These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 26461000)

  • 1. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
    Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
    Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
    Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Cockle JV; Rajani K; Zaidi S; Kottke T; Thompson J; Diaz RM; Shim K; Peterson T; Parney IF; Short S; Selby P; Ilett E; Melcher A; Vile R
    Neuro Oncol; 2016 Apr; 18(4):518-27. PubMed ID: 26409567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
    Rommelfanger DM; Wongthida P; Diaz RM; Kaluza KM; Thompson JM; Kottke TJ; Vile RG
    Cancer Res; 2012 Sep; 72(18):4753-64. PubMed ID: 22836753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.
    Alonso-Camino V; Rajani K; Kottke T; Rommelfanger-Konkol D; Zaidi S; Thompson J; Pulido J; Ilett E; Donnelly O; Selby P; Pandha H; Melcher A; Harrington K; Diaz RM; Vile R
    Mol Ther; 2014 Nov; 22(11):1936-48. PubMed ID: 25059678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
    Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
    Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
    Leveille S; Goulet ML; Lichty BD; Hiscott J
    J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.